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ABSTRACT
Physicians and patients have long been aware of
skin lesions at the sites of insulin injections,
referred to as lipodystrophy that can present as
lipoatrophy (LA) or lipohypertrophy (LH).
However, the reported prevalence of these
different skin lesions varies widely,
emphasizing the need for a correct
identification method. In this short review we
discuss LA and LH and also take into account
other skin lesions, such as bruising, as well as
different needle injuries, including those
associated with the subcutaneous injection of
pegvisomant (a drug aimed at counteracting the
high levels of growth hormone associated with
acromegaly), long-acting exenatide (a
glucagon-like peptide-1 receptor agonist), and
anti-tumor necrosis factor-alpha biologic agents
(used against Crohn’s disease). In these latter
cases specific studies are warranted to
understand the pathophysiological
background and possible prevention. However,
the most common lesion is still insulin
injection site-related LD, so a strong effort has
to be made to avoid the confusion generated by
previously misleading classifications which
were barely able to reliably distinguish
between LA and LH.
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DEFINITION OF LIPODYSTROPHY
Lipodystrophy (LD), a disorder of adipose tissue,
is one of the most common complications of
subcutaneous insulin injections and may
present as either lipohypertrophy (LH) or
lipoatrophy (LA). The latter is defined as a
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large, often deep, retracted scar on the skin that
results from serious damage to subcutaneous
fatty tissue [1]. Several features of LA suggest an
immunological etiology [2]: (1) it is more
frequent in patients with type 1 diabetes, and
mostly affects women—who often have other
signs of autoimmunity; (2) it is often
characterized by the presence of mast cells and
eosinophils in biopsy specimens and may be
responsive to topical 4% cromolyn sodium
preparations (an inhibitor of mast cells); (3) it
seems to be the result of a lipolytic reaction to
impurities or other components in some insulin
preparations, as its prevalence has dropped to
only 1–2% with the increasing use of purified
insulin [3, 4].
LH is a thickened ‘rubbery’ tissue swelling
which is mostly firm but may occasionally
present as a soft lesion as well, and thus it is
easily missed during a standard medical
examination. Although the exact etiology of
LH is unclear, several local factors appear to be
at play, including both the insulin molecule per
se—with its strong growth-promoting
properties—and repeated trauma caused by
poor injection habits, such as infrequent/
missed injection site rotation and/or frequent
needle reuse [1]. However, a large body of
evidence also lends support to a significant
association between LH and many other factors,
including female sex, low socioeconomic level,
high body mass index, as well as long-standing
disease and/or insulin treatment. LH lesions are
generally correctly identified during the course
of any accurate examination, although in
various published series the steps taken to do
so were not fully documented [5–7].
This article is based on previously conducted
studies, is fully ethics compliant, and does not
involve any new studies of human or animal
subjects performed by any of the authors.




Amissed diagnosis of LDmay havemajor clinical
consequences. The injection of insulin into parts
of the body affected by LD may cause wide
glycemic oscillations, including inappropriately
high glucose levels and ahigh rate of unexplained
hypoglycemic episodes, both of which are
scarcely responsive even large changes in insulin
dose [1, 8]. Programs aimed specifically at
educating patients with LD on proper injection
techniques has proven to be effective in
significantly reducing glucose oscillations [9].
Despite LH and LA on occasion being used
improperly as synonyms [3], we suggest that the
two concepts be kept separate.
Most studies suggest that insulin absorption
at areas affected by LH may be both delayed and
erratic, leading to the need for ever increasing
doses of insulin and worsening metabolic
control [10–14]. This in turn causes
unacceptable glucose oscillations due to a high
rate of serious hypoglycemic episodes followed
by rebound glucose spikes whenever patients
suddenly switch from affected injection sites to
normal ones. Under these conditions, the
economic burden of the disease increases for
both patients and the healthcare system.
Therefore, it is crucial that as many areas
affected by LH as possible are systematically
identified in order to educate patients on good
insulin injection habits. The reported
prevalence of LH in patients receiving insulin
injections varies widely in published studies [6],
possibly due to the lack of a well-structured
diagnostic flow-chart despite the world-wide
availability of suitable ultrasound and
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radiological methods [1, 15–24]. We recently
published a methodological paper on a
palpation technique that enables the clinician
to identify skin lipohypertrophic lesions in
diabetic patients receiving insulin [6]. We
therefore propose that diabetes teams be
formed at medical institutions which would
systematically follow that simple procedure we
describe for the diagnosis of LH at all insulin
injection sites and then implement and
hopefully progressively refine this procedure in
large-scale studies. In particular, unexplained
variations in glucose levels and/or unexplained
hypoglycemic episodes may alert healthcare
providers to look for LH in diabetic patients
receiving insulin injections.
BRUISING
Another original aspect of insulin
injection-related skin lesions is bruising at the
level of the injection site, as shown in Fig. 1.
Bruising is mentioned in several published
studies on insulin injections [25–28]. It is a
problematic side-effect of insulin injections
which disturbs diabetic patients due to the
resulting blemishes, for which there are as yet
no solutions. Unfortunately, in terms of both
patient and healthcare provider perspectives,
injection-related problems negatively affect the
overall number of shots diabetic patients are
willing to take [28]. In fact, in some studies
one-half of the patients reported mentioning
injection-related problems to their healthcare
providers who were unable to resolve the
associated pain and bruising [28, 29].
In a series of 780 insulin-treated adults with
type 2 (n = 556) or type 1 (n = 223) diabetes
mellitus on a multiple daily injection regimen
(4 shots/day), we identified 46.2% of patients
had areas affected by LH, with a mean lesion
diameter of 4.8 ? 3.1 cm, but LA was quite
uncommon (3.2%) (unpublished data). In this
same series, 33.2% of patients showed bruising,
either associated with LH (n = 178, 53.9%) or
isolated (n = 156, 46.6%), independent of the
use of antiplatelet and/or anticlotting drugs
(unpublished data).
Fig. 1 Two examples of bruising due to insulin injection, in the absence of any antiplatelet and/or anticlotting agents
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It is important to note that injection
site-related adverse events, such as pain,
redness, bruising, and bleeding, are significant
barriers to patient adherence to treatment
regimens involving multiple daily injections.
This is especially important when physicians
and/or healthcare providers are not sufficiently
experienced or possess insufficient knowledge
to provide assistance [28–30] or when the
doctor–patient relationship is unsatisfactory
[29].
To fill this gap, during the last few years an
interesting exchange of experiences has
developed among patients through various
networks, beginning with the American
Diabetes Association Community [31]. Such
forums have enabled diabetic patients
themselves to propose several interesting
solutions, including a sufficiently long
injection time, very thin and short needles,
and a careful injection site rotation technique.
However, specific investigations are still
warranted to assess reasons behind such
complications associated with the injection
site and to identify scientifically sound
solutions aimed at improving patient
adherence to insulin therapy.
OTHER, GENETIC OR ACQUIRED
LIPODYSTROPHIES, INCLUDING
THOSE ASSOCIATED TO HUMAN
IMMUNODEFICIENCY VIRUS
After taking into consideration all of the
concepts mentioned in the preceding sections,
it should be noted that LD does not represent
only a single complication of insulin
treatment—rather, a number of different
clinical pictures, all falling under the name
‘LD’, have also been reported to be associated
with skin lesions. These are heterogeneous,
genetic, or acquired disorders of skin fat. It is
well known that exogenous proteins may
induce local inflammatory reactions and that
the injection of different medications may
cause local adverse events.
The most prevalent subtype of acquired
non-insulin treatment-related LD occurs in
human immunodeficiency virus-infected
patients on long-lasting protease
inhibitor-containing, highly active
antiretroviral therapy. This type of LD likely
results from lipid and/or glucose metabolic
disorders, with the latter ranging from fasting
hyperglycemia to insulin resistance/
hyperinsulinemia [32, 33].
PEGVISOMANT
Another reversible LD association reported to
date is the one between LH and pegvisomant
injections in patients with acromegaly. Several
cases of this association have been published
[34] and, interestingly enough, LH was reported
to have regressed in all patients when the
medication was discontinued or a regular
injection site rotation technique was




Another type of palpable, yet often invisible
subcutaneous nodule is the one occurring
following subcutaneous shots of long-acting,
once-weekly formulation of exenatide (EQW), a
glucagon-like peptide-1 receptor agonist (GLP-1
RA) [36]. This adverse event was reported in
registration studies, together with other
injection site-related adverse events [37], among
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which itching was the most common, although
its rate appeared to wane over time, from 11.0%
between weeks 4 and 6 to 4.6% between weeks 28
and 30 [38]. An informal communication from
the DURATION-1 study staff indicated that
nodules were generally 0.5–0.75 cm in diameter,
and their incidence seemed to decline over time
and slowly vanished, even inpatientswith several
earlier similar episodes [37–39]. As EQW uses a
PLG [poly(D,L-lactide-co-glycolide)] microsphere
technology, LH lesions were thought to be the
result of a typical foreign body local reaction [39],
implying the migration of polymorphonuclear
leukocytes, monocytes/macrophages, and
lymphocytes [40].
Despite these reports, no published studies
are available on any injection site-related
adverse effects involving EQW. Neither is
information available on any possible skin
reaction-driven changes in EQW
pharmacokinetics and pharmacodynamics or
on any related potential clinical consequences.
In addition, no reports are available in the
literature on any injection-related skin lesions
associated to other daily or weekly GLP-1 RA
formulation.
ANTI-TUMOR NECROSIS FACTOR
The anti-tumor necrosis factor (anti-TNF)
biologic agents used against Crohn’s disease
have been associated with a number of injection
site reactions, including redness, itching,
bruising, pain, or swelling [41]. These have
been commonly observed with subcutaneous
protein injections even in the combined safety
trial [42–44]. However, once again no published
reports are available on anti-TNF-related
lipodystrophic injuries similar to those due to
insulin injections, and therefore specific studies




All of these different types of skin lesions can be
confounding, especially when no clear-cut
differentiation can be made between
well-defined lesions with different morphology
and pathogenesis, such as insulin-related LH
and LA. Specifically, LH and LA are still
occasionally confused [9], even though the
latter is a scarring lesion and is therefore quite
different from LH in terms of both morphology
(see Fig. 2) and pathogenesis. Indeed, while
confusing these two lesion types may have
been justified back in 2002, when a letter to
the editor published in Diabetes Care proposed a
three-stage classification for insulin-related LD
despite little being admittedly known about the
nature and causes of described phenomena
[3, 7, 23]. However, given the state of current
scientific knowledge, no confusion should be
made between lesions having so different an
appearance and metabolic consequences.
In conclusion, even today little information
is available on possible clinical consequences of
local injection-related side-effects of
subcutaneous medications against diabetes
(exenatide and other GLP-1-RA), acromegaly
(pegvisomant), or Crohn’s disease (anti-TNF).
Based on evidence showing that insulin
shots are the most frequent factors associated
to skin lesions, we suggest that precautions
recommended for insulin injections may be
adopted for all other subcutaneously injected
drugs as well. In particular, local damage may be
minimized through the use of very short and
thin needles and a careful injection site rotation
method [45]. However, dedicated studies are
needed to support this hypothesis.
Conversely, no cases of LA associated with
subcutaneous use of drugs other than insulin
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have been reported to date. LA lesions are even
quite rare in insulin-treated patients, since the
most numerous patient series described in the
literature adds up to 24 subjects [4]. LA has been
suggested to be related to the use of animal
insulins [46], and the prevalence of LA lesions
has been noted to have declined considerably
following the introduction of new insulin
analogs on the market, although some cases of
LA have also been reported to be associated with
the latter as well.
Given the state of current knowledge, any
confusion between LA and LH is no longer
justified from a clinical perspective, as insulin
has a much higher chance to penetrate into the
subcutaneous muscle tissue when injected into
areas affected by LA, thus eventually causing
more severe hypoglycemic events and at a
much higher frequency than that observed
with LH.
Prevention of wide glycemic variations and
the risk of hypoglycemia is primarily based on
patient education with respect to the need for
regular injection site rotation and avoidance of
areas affected by LA or LH. In fact, we suggest
that patients be educated so as to be able to
identify LA and LH themselves in order to avoid
damaged areas as much as possible [3, 23].
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